Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 301–400 of 1,000
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
Gee, M. F. W., Chalfin, D. B., Devol, E. B., Levy, H. R., Boltyenkov, A., Casale, M. G., & Sanyal, A. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70846 · Cited by 5
Self-citationCurrent therapeutic landscape and future treatment perspectives of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10672-8 · Cited by 7
“Both have demonstrated significantly greater histological MASH resolution and fibrosis regression than placebo 20,24 .”
InfluentialSemaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
Colhoun, H. M., Lincoff, A. M., Ryan, D. H., Lingvay, I., Kahn, S. E., Hovingh, G. K., Hardt‐Lindberg, S., Oral, T. K., Weeke, P. E., Linder, M., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag524 · Cited by 7
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Optimize hypertension management to tackle the CVD burden in MASLD
Kasper, P., Demir, M., & Steffen, H. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.07.007 · Cited by 4
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 10
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review
Torres, J. V. D., Guerrero, V. R. V., Gómez, J. P. V., Miranda, F. J. P., Álvarez, L. R. O., Insignares, J. D. L., Mares, M., Ortiz, H. M. R., & Mendoza‐Torres, E. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251382048 · Cited by 4
Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis
Simon, T. G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2504717 · Cited by 7
Redefining End Points in MASH Cirrhosis
García–Tsao, G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505834 · Cited by 4
Management of Obesity in Psoriasis Consultations
Nicolau, J., López‐Ferrer, A., & de la Cueva, P. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01664-7 · Cited by 5
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3
Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD
Eppler, N., Jones, E., Ahamed, F., & Zhang, Y. (2025) · Livers · doi:10.3390/livers5030033 · Cited by 5
“…(GLP-1) receptor agonists (e.g., liraglutide, semaglutide), GIP/GLP-1 dual receptor agonists (e.g., tirzepatide), glucagon/GLP-1 dual receptor agonists (e.g., pemvidutide, survodutide), and glucagon/GIP/GLP-1 triple receptor agonists (e.g., efocipegtrutide) for the treatment of MASH [14–18].”
Arredouani, A. (2025) · Diabetologia · doi:10.1007/s00125-025-06527-y · Cited by 3
Shah, A., Mohammadi, A., Haq, A., Walji, D., & Zevin, B. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08246-0 · Cited by 4
“[ 10] While only 1 in 12 men and 1 in 10 women with class I obesity (BMI 30–34.99) achieve a weight-reduction of 5% over a 1-year period through lifestyle modification alone [11] – the minimum reduction in weight needed to reduce progression of MASLD [12] – pharmacologic therapies, including GLP-1…”
InfluentialYu, W., Liu, Y., Le, S., Xiao, Y., Chen, X., Wang, J., & Gao, F. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70174 · Cited by 4
“…ef fi cacy of Sema as a GLP-1RA in improving glycemic control and MASLD in T2DM patients has been con-fi rmed by SUSTAIN and other clinical trials 6,19 – 21 , drug therapy alone may not be as effective as exercise combined with drug therapy in improving body weight control and lipid metabolism…”
Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?
Mademlis, C., Patoulias, D., Koufakis, T., Teperikidis, E., Γιουλεμέ, Ό., & Doumas, M. N. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2573785 · Cited by 3
“Semaglutide emerges as a compelling candidate in the pharmacologic management of MASH and moderate-to-advanced fibrosis, with data from ESSENCE trial demonstrating statistically significant improvements in hepatic histology and cardiometabolic parameters [1].”
InfluentialDavis, J. P. E., Henry, Z., Sharma, P., Tsunoda, S. M., Han, H., Orandi, B. J., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., Argo, C. K., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.10.008 · Cited by 3
Frey, L. J., Fuchs, M., Ward, R. C., Gebregziabher, M., Nasir, A. B., Natarajan, Y., Schreiner, A. D., Rockey, D. C., & Syn, W. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334715 · Cited by 4
“Based on a successful phase 3 clinical trial [27], the FDA has approved semaglutide, a glucagon-like peptide-1 (GLP-1), for the treatment of patients with MASH and stage 2 or 3 fibrosis.”
Norlin, J., Dermit, M., Sidiropoulos, N., Galsgaard, E. D., Hansen, H. H., Feigh, M., Veidal, S. S., Latta, M. R., Henriksson, E., & Andersen, B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331665 · Cited by 3
Stefanakis, K., Mingrone, G., George, J., & Mantzoros, C. S. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.029 · Cited by 5
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury
Săndulescu, S. M., Ghiga, D. Ș., Tudoraşcu, D. R., Săndulescu, L., Mită, A., Urhuț, M. C., & Taisescu, C. I. (2025) · Life · doi:10.3390/life15121805 · Cited by 4
“Secondary endpoints showed improvements in lipids, blood pressure, and markers of systemic inflammation [146].”
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care
Mazza, A. D. (2025) · Cureus · doi:10.7759/cureus.98153 · Cited by 4
“…rise in metabolic risk during the menopausal transition, targeted trials in perimenopausal and postmenopausal women are warranted, with attention to hormone status, body-composition change, cardiovascular risk, and dose adjustments of thyroid medications during weight loss [1,2,66] (Figure 2 ).”
Wang, Y., & Peng, J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108054 · Cited by 3
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
“A one-stage improvement in fibrosis without worsening of steatohepatitis was achieved in 36.8% vs 22.4% (Δ 14.4 pp; 95% CI, 7.5 to 21.3; P < 0.001) [57,58].”
InfluentialFeng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Laitinen, A., Käräjämäki, A., Käräjämäki, A. J., Kurki, S. H., Hakaste, L., Asplund, O., Hultman, J., Lahti, K., Lehtovirta, M., Ahlqvist, E., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70983 · Cited by 3
Highly Reproducible, Vendor‐Agnostic, Motion‐Insensitive Liver PDFF Mapping at 0.55T , 1.5T , and 3T
Tang, J., Tamada, D., Nielsen, J., Starekova, J., Heidenreich, J. F., Schön, F., Anagnostopoulos, A. A., Roshanshad, A., Mao, L., Fujita, S., et al. (2025) · Magnetic Resonance in Medicine · doi:10.1002/mrm.70223 · Cited by 3
Circulating histones as potential biomarkers of MASLD-MASH-HCC progression
Tsoneva, D. K., Búzová, D., Bianco, S. D., Braghini, M. R., Andolina, G., Liguori, A., Ambrosio, F. D., Urbani, A., Gasbarrini, A., Pompili, M., et al. (2025) · Epigenomics · doi:10.1080/17501911.2025.2611415 · Cited by 6
Mechanisms of scramblases in regulating hepatic lipoprotein secretion and autophagy
Chen, A., Zhang, C., Ding, W., & Ni, H. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.100979 · Cited by 6
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
The important role of comorbidities in the management of obesity
Barenbaum, S. R., Tchang, B. G., & Aronne, L. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag012 · Cited by 5
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Zhai, D., Ni, J., Shao, X., Zhao, W., Chen, Y., Fan, K., Li, J., Shen, Y., Lin, A., Hu, W., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001708 · Cited by 4
Ogbu, C. E., Ogbu, S. C., Ogbu, C. P., & Umerah, C. (2026) · iLiver · doi:10.1016/j.iliver.2026.100222 · Cited by 4
“74,75 Mechanistically, GLP-1 – based therapies activate AMPK/SIRT1 signaling, enhance autophagy, improve mitochondrial function, and dampen inflammatory pathways in liver models 76-78 which are processes central to aging biology.”
Laurence, A., Gandhi, S., Nylén, E., & Sen, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.011 · Cited by 3
Götzinger, F., Stolte, T., Reichl, J. J., von Peter, A., Kunz, M., Wild, M. G., Wagener, M., Kaiser, C., Mueller, C. E., Westermann, D., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag075 · Cited by 3
Facciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Kobayashi, T., Yoneda, M., Duseja, A., Fan, J.-G., Nersesov, A., & Nakajima, A. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.010 · Cited by 3
Yan, J., Wang, J., Jian, F., Cui, X., Zhang, Y., Yang, X., Gao, Q., Ding, Z., 汤钊猷, Fan, J., et al. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70033 · Cited by 7
“GLP‐1 receptor agonists such as semaglutide and liraglutide have demonstrated anti‐inflammatory effects and the capacity to reduce hepatic fat deposition in patients with MASH [167, 168].”
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Kim, B. R. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70227 · Cited by 4
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 6
Sierra, L., Liu, L., Khurana, A. T., Patel, R., Chatterjee, A., Firkins, S. A., & Simons-Linares, R. (2026) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.93a.25082 · Cited by 3
“15 Resmetirom, which does not require weight loss for effi cacy, may be a better option for lean patients with MASH fi brosis.”
Cobbold, J., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 6
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
“The safety profile was consistent with prior evidence, with no new liver-related safety signals reported to date [100].”
InfluentialZhou, X., Lv, J., Liu, W., Mu, Y., Chen, G., Chen, J., Liu, P., & Fu, Y. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.05.013 · Cited by 3
Basta, D., Refaei, A. H. A., Msinjili, L., Frishman, W. H., & Lebovics, E. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001298 · Cited by 3
Tang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3
Oyewole, S. O., & Owosho, A. A. (2026) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2026.06.002 · Cited by 3
Mogna-Peláez, P., & Guasch‐Ferré, M. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101684 · Cited by 4
“…improvement in metabolic dysfunction-associated steatotic liver disease (MASLD) spectrum, including reduction in hepatic steatosis and, in patients with established steatohepatitis, histologic improvement and fibrosis regression in metabolic dysfunction-associated steatohepatitis [2 ‒ 4].”
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 5
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents
Qasim, A., Alataa, R., Veena, F., & Shehi, E. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1850915 · Cited by 4
Díaz, L. A., Pose, E., Israelsen, M. E., & Loomba, R. S. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01240-6 · Cited by 5
Zhou, X., Jeong, S., Chen, Q., Targher, G., Byrne, C. D., Chew, N. W., Younossi, Z. M., Lip, G. Y. H., Tilg, H., George, J., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01255-z · Cited by 3
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
Zatta, R., da Silva, L. S., Felga, G. E. G., & Pimentel, C. F. M. G. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107837 · Cited by 3
Chen, A., Nguyen, K., Niu, M., Jiang, X., Yu, X., Xie, Y., Liu, W., Davidson, N. O., Ding, W., & Ni, H. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101751 · Cited by 4
MASLD in the cardiovascular–kidney–metabolic health framework: what does it add to the table?
Ha, K. H., Kim, D. J., & Lee, H. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf549 · Cited by 5
Semaglutide targets MASH molecular pathways beyond weight loss
Michel, M. S., & Schattenberg, J. M. (2025) · Nature Medicine · doi:10.1038/s41591-025-03927-w · Cited by 4
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST
Ravaioli, F. (2025) · Hepatology · doi:10.1097/hep.0000000000001421 · Cited by 3
Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals
Akinrimisi, O. I., Koning, M., Scheijen, J. L. J. M., Meijnikman, A. S., Sindhunata, D. P., Bruin, S. C., van de Laar, A. W. J. M., Franken, R. J., Acherman, Y. I. Z., Gerdes, V. E. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16643 · Cited by 2
“…is also significant fibrosis, and multiple clinical trials in the MASLD/MASH field use fibrosis stage 2 as a criterion for inclusion in drug trials 49,50 There are more individuals without diabetes than with diabetes; therefore, further research in a larger, more encompassing cohort will be…”
Lin, J., Green, V., Sohal, A., & Roytman, M. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002234 · Cited by 3
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?
Nwoguh, C. A., Byrne, C. D., Reinson, T., & Buchanan, R. M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2546597 · Cited by 2
“These include peroxisome proliferator-activated receptor agonists [39] and multiple incretin-based therapies such as semaglutide [40], a glucagon-like peptide-1 (GLP-1) receptor agonist; tirzepatide [41], a dual glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory…”
Attia, A. M., Zavareh, M. S. R., Yeo, Y. H., Kwak, M., Kim, H., Noureddin, M., & Yang, J. D. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000806 · Cited by 2
“[32] A recent phase III clinical trial [33] demonstrated that semaglutide treat-ment in patients with MASH and moderate or advanced liver fibrosis significantly improved liver histology by achieving steatohepatitis resolution without fibrosis worsening, reducing fibrosis without steatohepatitis…”
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2
Ghusn, W., Sridharan, M., Fromer, R., Ozdemir, M., Haff, M. G., & Vargas, E. J. (2025) · Biomedicines · doi:10.3390/biomedicines13102437 · Cited by 2
“Although hepatocytes do not directly express GLP-1 receptors, there is overwhelming evidence to suggest that the use of GLP-1 receptor agonists (GLP-1RA; e.g., semaglutide) is correlated with improved hepatic steatosis and slowing of fibrosis [33–37].”
Practical Considerations for the Use of Semaglutide in MASH
Odenwald, M. A., & Rinella, M. E. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003816 · Cited by 2
Self-citationPugliese, N., Spertino, M., Mercurio, M., Ciardullo, S., Perseghin, G., Hassan, C., Vettor, R., Petta, S., & Aghemo, A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.018 · Cited by 2
Huang, X., Zhu, T., Li, S., Liu, T., Lin, S., Liang, H., Zhong, M., Sun, X., Chen, L., Bai, H., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001612 · Cited by 5
Efficacy of non-pharmacological treatments in pediatric MASLD: a review of the literature
Mosca, A., Braghini, M. R., Pietrobattista, A., Alisi, A., & Vania, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1667377 · Cited by 2
Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 2
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Alshaikh, A., Alshehri, A., Alzubaidi, L. M. Y., Elbadawi, H., Alsaeed, A. H., Almehthel, M. S., Aldahash, R., Alsabaan, F., Alotaibi, M. S., Alghamdi, K. A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01826-4 · Cited by 2
Nian, F., Chen, Y., Chen, J., Jiang, Q., Meng, F., Chen, Z., Lu, X., Shen, X., & Li, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149451 · Cited by 2
The dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial
Tacke, F. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02304-9 · Cited by 3
Wood, E. M., Akande, R. O., Iqbal, I., & Albert, S. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70314 · Cited by 2
“34 The larger phase 3 study by Sanyal 2025 16 was sufficient for providing evidence for FDA approval for MASH (rr = 1.64, CI: 1.28, 2.11, p 0.001).”
InfluentialInterorgan crosstalk in metabolic dysfunction-associated steatotic liver disease
Yang, R., Fang, Z., He, F., & Wang, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003927 · Cited by 3
Wauquier, F., Chavanelle, V., Bouchard‐Mercier, A., Boutin-Wittrant, L., Otero, Y. F., Krisa, S., Valls, J., Joubioux, F. L., Pereira, B., Roux, V., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32556-z · Cited by 3
“However, these treatments designed to cure rather than to prevent, evidence side effects (e.g., muscle related issues for statins; gastrointestinal adverse events for both resmetirom and semaglutide) 14,15 and may be quite expensive for patients and healthcare systems 19 .”
Drug treatment of MASH from none to (too) many options?
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001378 · Cited by 2
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“Part 1 of the study has been completed and published, which showed that sema-glutide led to MASH resolution in 62.9% of patients, com - pared to 34.3% on placebo (ETD − 28.7%, p 0.001) [66].”
InfluentialZhang, J., Mohamed, A., Marsden, J. E., Bays, C., & Schreiner, A. D. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251406217 · Cited by 2
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
Low Rates of MASLD Screening in Young Adults With Type 2 Diabetes: A Retrospective Cohort Study
de Crecy, C., yang, Q., Liu, M., Yin, R., & Sharma, A. R. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf223 · Cited by 2
“As therapies now exist that slow the progression and even reverse fibrosis (7, 8), screening for at-risk MASH in people with T2D is recommended by the American Diabetes Association and other organizations (9-11).”
Liver Fibrosis: Current Treatments, Bottlenecks, and Future Prospects for Translational Medicine
Nair, D. G., & Weiskirchen, R. (2026) · Sci · doi:10.3390/sci8010009 · Cited by 2
“These effects translate into secondary, but clinically meaningful improvements in hepatic inflammation and fibrosis [24].”
Hertzer, L., Siegel, R., Kharofa, R. Y., Stackpole, K., & Mahabee‐Gittens, E. M. (2026) · Childhood Obesity · doi:10.1177/21532176251413898 · Cited by 3
Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity
O'Connor, R. G. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.000039 · Cited by 2
Savvidou, S., Augousti-Varela, E., Damianakou, A., Chalkias, M., & Stergiou, I. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251409025 · Cited by 2
Mahalingam, S., Bellamkonda, R., Kharbanda, K. K., Ethiraj, O., Nagarajan, N., Guda, C., Sharma, K., Schott, M. B., Ca, C., Leggio, L., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118924 · Cited by 2
Long-Read Isoform Sequencing Reveals Aroclor1260-Induced Isoform Usage in Mouse Livers
Petri, B. J., Piell, K. M., Wahlang, B., Chariker, J. H., Rouchka, E. C., Cave, M. C., & Klinge, C. M. (2026) · Genes · doi:10.3390/genes17020126 · Cited by 2
“There is only one therapeutic agent, Resmetirom, that is FDA-approved for treating MASLD [5], and semiglu-tide was recently approved for treating metabolic-associated steatohepatitis (MASH) [6].”
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
“63 The fact that the phase III RCT achieved the fibrosis regression endpoint is in line with expectations based on the robust effect on MASH resolution, illustrating the importance of a sufficiently large sample size to overcome sources of variability when the effect size is modest.”
Bartholdy, A., Moseholm, K. F., Nielsen, P. Y., Albrechtsen, N. J. W., Gluud, L. L., & Jensen, M. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01796-x · Cited by 3
MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review
Ștefan, A. G., Mitrea, A., Clenciu, D., Vladu, I. M., Roșu, M. M., Timofticiuc, D. C. P., Gheonea, T. C., Efrem, I. C., Amzolini, A. M., Vladu, B. E., et al. (2026) · Medicina · doi:10.3390/medicina62020325 · Cited by 5
“Participants treated with semaglutide experienced a mean body weight decrease of 10.5%, and 2.0% in those receiving placebo [118].”
Influential
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.